Table 1.
Baseline characteristics of the angiographic cohort.
| MACE (3 year) |
AER quartiles |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic | All Subjects (N = 997) | No (N = 848) | Yes (N = 149) | P value | Q1 (n = 249) | Q2 (n = 249) | Q3 (n = 249) | Q4 (n = 250) | P value |
| Age (yr) | 62.7±10.6 | 61.9±10.5 | 67.3±9.9 | <0.0001 | 61.2±10.2 | 62.4±9.6 | 63.5±10.9 | 63.6±11.4 | 0.0491 |
| Male (%) | 65.6 | 65.8 | 64.4 | 0.82 | 73.9 | 72.7 | 63.5 | 52.4 | <0.0001 |
| Diabetes (%) | 36.1 | 34.3 | 46.3 | 0.0066 | 40.0 | 36.1 | 38.6 | 30.0 | 0.1056 |
| Hypertension (%) | 72.7 | 71.6 | 78.9 | 0.08 | 74.6 | 71.3 | 73.5 | 71.5 | 0.8146 |
| Smoking (%) | 66.6 | 66.0 | 69.8 | 0.42 | 69.1 | 71.9 | 65.1 | 60.4 | 0.0384 |
| LDL-C (mg/dL) | 96.0 (76.0– 118.0) | 96.0 (77.0– 118.0) | 92.0 (73.0– 116.0) | 0.17 | 91.0 (73.0– 115.0) | 96.0 (76.0– 122.0) | 97.0 (81.0– 114.0) | 97.5 (77.0– 119.0) | 0.0970 |
| HDL-C (mg/dL) | 33.8 (28.1– 41.2) | 34.1 (28.2– 41.5) | 32.5 (26.9– 39.3) | 0.07 | 29.1 (24.6– 34.3) | 30.5 (26.7– 36.1) | 34.3 (30.2– 40.4) | 43.5 (36.1– 53.0) | <0.0001 |
| Lp(a) (mg/dL) | 16.4 (6.6– 60.8) | 15.9 (6.6– 57.6) | 20.4 (6.7– 66.5) | 0.32 | 12.3 (6.6– 48.7) | 18.8 (6.4– 61.3) | 16.4 (7.2– 55.7) | 17.7 (7.6– 65.2) | 0.1876 |
| Total cholesterol (mg/dL) | 161.2 (140.5– 188.8) | 161.4 (141.3– 189.2) | 160.0 (135.0– 186.0) | 0.31 | 154.2 (132.0– 188.9) | 159.6 (136.7– 187.7) | 161.2 (142.6– 181.3) | 171.8 (148.2– 193.9) | 0.0006 |
| Triglycerides (mg/dL) | 116.0 (84.0– 172.0) | 114.5 (84.0– 172.2) | 127.0 (85.0– 170.0) | 0.47 | 141.0 (91.0– 221.0) | 132.0 (88.0– 187.0) | 112.0 (88.0– 153.0) | 97.0 (75.0– 132.8) | <0.0001 |
| apoA1 (mg/dL) | 115.0 (103.0– 131.0) | 116.0 (103.0– 132.0) | 113.0 (100.0– 124.0) | 0.0164 | 104.0 (93.0– 115.0) | 110.0 (101.0– 120.0) | 118.5 (107.0– 130.0) | 136.0 (122.0– 155.0) | <0.0001 |
| hsCRP (mg/L)a | 2.47 (1.09– 5.99) | 2.27 (0.99– 5.47) | 3.65 (1.89– 8.51) | <0.0001 | 3.12 (1.28– 8.16) | 2.24 (1.03– 5.32) | 2.21 (0.97– 4.67) | 2.56 (1.13– 5.78) | 0.0116 |
| Statin usage (%) | 58.8 | 59.3 | 55.7 | 0.46 | 63.9 | 63.5 | 55.4 | 52.4 | 0.0166 |
| Aspirin (%) | 71.6 | 72.2 | 68.5 | 0.41 | 76.3 | 67.1 | 73.1 | 70.0 | 0.1210 |
| CAD (%)b | 78.5 | 76.6 | 89.3 | 0.0008 | 88.3 | 83.5 | 75.8 | 66.3 | <0.0001 |
| PAD (%)c | 24.0 | 21.9 | 35.6 | <0.0001 | 24.1 | 26.5 | 26.1 | 19.2 | 0.2019 |
| CVD (%)d | 81.1 | 79.4 | 90.6 | 0.002 | 89.6 | 86.3 | 78.3 | 70.0 | <0.0001 |
Values are mean ± SD, %, or median (interquartile range).
P values were calculated by Wilcoxon rank-sum test for continuous data and Pearson’s chi-square test for categorical factors.
a
High-sensitivity C-reactive protein.
b
Coronary artery disease: myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, angiography ≥50% stenosis in one or more major coronary vessels.
c
Peripheral artery disease: noncoronary arterial disease including carotid artery stenosis, upper extremity artery stenosis, mesenteric artery stenosis, renal artery stenosis, and lower extremity peripheral artery disease.
d
Cardiovascular disease: CAD and/or peripheral vascular disease.